SRRK
NASDAQScholar Rock Holding Corporation
News · 26 weeks580%
2026-03-012026-08-23
Mix3090d
- Insider12(40%)
- Earnings10(33%)
- SEC Filings7(23%)
- Other1(3%)
Latest news
25 items- PRScholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and JapanUnder FDA guidance, Scholar Rock has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA); FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facility Company is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time through September 30, 2026 Prescription Drug User Fee Act (PDUFA) date; robust supply of apitegromab commercial vials from alternate fill-finish facility available upon FDA approval Following Catalent Indiana Official Action Indicated (OAI) inspection classificatio
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding CorporationSCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
- PRScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 14,889 shares of common stock and inducement restricted stock units, covering an aggregate of 37,058 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is us
- PRScholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action DateToday, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (OAI) Scholar Rock continuing to collaborate closely with FDA and under their guidance, will remove Catalent Indiana fill-finish facility from apitegromab BLA FDA review of second fill-finish facility progressing; Data package for FDA review of second fill-finish facility, as agreed to during March 2026 Type C meeting, has been submitted in advance of agreed upon timeline Robust supply of apitegromab commercial vials from second fill-finish facilit
- SECScholar Rock Holding Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Scholar Rock Holding Corp (0001727196) (Filer)
- SECSEC Form 424B5 filed by Scholar Rock Holding Corporation424B5 - Scholar Rock Holding Corp (0001727196) (Filer)
- SECSEC Form 10-Q filed by Scholar Rock Holding Corporation10-Q - Scholar Rock Holding Corp (0001727196) (Filer)
- SECScholar Rock Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Scholar Rock Holding Corp (0001727196) (Filer)
- PRScholar Rock Reports Second Quarter 2026 Financial Results and Recent Business HighlightsApitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date FDA review of second fill-finish facility progressing; Data package for FDA review of second fill-finish facility has been submitted; Ample supply available for commercialization upon FDA approval Scholar Rock is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time through September 30, 2026 Company engaging with European Medicines Agency (EMA) on next steps f
- PRScholar Rock to Present at the Canaccord Genuity 46th Annual Growth ConferenceScholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026 at 1:30 p.m. ET. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be available for approximately 90 days. About
- PRScholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab CHMP Opinion expected following resolution of Catalent Indiana classification status or inclusion of second fill-finish facility in MAA Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today provided an update on the anticipated timing of a Committee for Medicinal Products for Human Use (CHMP) opinion for the apitegromab marketing authorisation applic
- PRScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 118,586 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 33,987 shares of common stock and inducement restricted stock units, covering an aggregate of 84,599 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is u
- PRScholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026Scholar Rock (NASDAQ:SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to "Events and Presentations" in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. An archived replay of the webcast will be available on the Company’s website for
- INSIDERDirector Burow Kristina sold $164,064 worth of shares (3,053 units at $53.74), decreasing direct ownership by 3% to 114,657 units (SEC Form 4) (tax liability)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Flier Jeffrey S. sold $164,490 worth of shares (3,053 units at $53.88), decreasing direct ownership by 10% to 27,856 units (SEC Form 4) to cover withholding tax4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Gilman Michael sold $137,058 worth of shares (2,544 units at $53.87), decreasing direct ownership by 4% to 59,511 units (SEC Form 4) (tax withholding)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Reed Joshua sold $164,067 worth of shares (3,053 units at $53.74), decreasing direct ownership by 14% to 19,518 units (SEC Form 4) to cover taxes4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Peng Katie sold $293,405 worth of shares (5,446 units at $53.88), decreasing direct ownership by 14% to 34,301 units (SEC Form 4) (withholding tax)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- SECSEC Form 144 filed by Scholar Rock Holding Corporation144 - Scholar Rock Holding Corp (0001727196) (Subject)
- SECSEC Form 144 filed by Scholar Rock Holding Corporation144 - Scholar Rock Holding Corp (0001727196) (Subject)
- PRScholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHDScholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, announced today that it will present new clinical data and research updates at Cure SMA’s Annual SMA Research & Clinical Care Meeting being held June 24-26, 2026, in Orlando, Florida and the FSHD Society’s 2026 International Research Congress on FSHD being held June 25-26, 2026 in Chicago, Illinois. Presentations will feature updates and analyses related to the Company’s neuromuscular research portfolio, inclu
- PRScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 50,936 shares of common stock and inducement restricted stock units, covering an aggregate of 83,409 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is u
- INSIDERDirector Flier Jeffrey S. was granted 6,839 shares, increasing direct ownership by 28% to 30,909 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Reed Joshua was granted 6,839 shares, increasing direct ownership by 43% to 22,571 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Brudnick Richard was granted 6,839 shares, increasing direct ownership by 45% to 21,896 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
SRRK FAQ
7 questionsWhat does Scholar Rock Holding Corporation do?
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody...Where does SRRK stock trade?
Scholar Rock Holding Corporation (SRRK) is listed on NASDAQ.What sector and industry is SRRK in?
Scholar Rock Holding Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Scholar Rock Holding Corporation go public?
Scholar Rock Holding Corporation (SRRK) completed its IPO in 2018.What are analysts saying about SRRK?
Scholar Rock Holding Corporation has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-04-21. Recent price targets range from $4200.00 to $4500.00.What companies are similar to SRRK?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SRRK side-by-side with any of them on Quantisnow.How can I track SRRK on Quantisnow?
Quantisnow aggregates Scholar Rock Holding Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRRK to receive live email and push alerts on every new disclosure.